MX338610B - Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa. - Google Patents

Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.

Info

Publication number
MX338610B
MX338610B MX2013015002A MX2013015002A MX338610B MX 338610 B MX338610 B MX 338610B MX 2013015002 A MX2013015002 A MX 2013015002A MX 2013015002 A MX2013015002 A MX 2013015002A MX 338610 B MX338610 B MX 338610B
Authority
MX
Mexico
Prior art keywords
sulbactam
beta
pharmaceutical compositions
lactamase inhibitor
acceptable salt
Prior art date
Application number
MX2013015002A
Other languages
English (en)
Other versions
MX2013015002A (es
Inventor
Manesh Vithalbhai Patel
Sachin Bhagwat
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2013015002A publication Critical patent/MX2013015002A/es
Publication of MX338610B publication Critical patent/MX338610B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen composiciones y métodos para tratar o prevenir infecciones bacterianas. Las composiciones farmacéuticas comprenden típicamente una cantidad farmacéuticamente efectiva de: (a) sulbactam o su sal farmacéuticamente aceptable, y (b) por lo menos un inhibidor de beta-lactamasa o una sal de ella, aceptable para uso farmacéutico, a condición de que el inhibidor de beta lactamasa no sea sulbactam.
MX2013015002A 2011-07-26 2011-10-04 Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa. MX338610B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2125MU2011 2011-07-26
PCT/IB2011/054349 WO2013014496A1 (en) 2011-07-26 2011-10-04 Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor

Publications (2)

Publication Number Publication Date
MX2013015002A MX2013015002A (es) 2014-10-22
MX338610B true MX338610B (es) 2016-04-25

Family

ID=44925586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015002A MX338610B (es) 2011-07-26 2011-10-04 Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.

Country Status (13)

Country Link
US (1) US9744160B2 (es)
EP (1) EP2736508A1 (es)
JP (1) JP5808860B2 (es)
KR (1) KR101737167B1 (es)
CN (1) CN103687598B (es)
AU (1) AU2011373911B2 (es)
BR (1) BR112013032711A2 (es)
CA (1) CA2842777C (es)
MX (1) MX338610B (es)
NZ (1) NZ616806A (es)
RU (1) RU2560846C1 (es)
WO (1) WO2013014496A1 (es)
ZA (1) ZA201307956B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ617104A (en) * 2011-07-26 2015-05-29 Wockhardt Ltd Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
CA2869051A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. Isoxazole .beta.-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8933233B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
EP2970338A1 (en) 2013-03-14 2016-01-20 Merck Sharp & Dohme Corp. Crystalline form of a beta-lactamase inhibitor
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
MX2016005161A (es) * 2013-10-22 2016-10-05 Wockhardt Ltd Composiciones farmaceuticas que comprenden agentes antibacterianos.
IN2013MU03421A (es) * 2013-10-30 2015-07-17 Wockhardt Ltd
IN2014MU00859A (es) * 2014-03-14 2015-10-02 Wockhardt Ltd
BR112016022439A2 (pt) * 2014-03-29 2017-08-15 Wockhardt Ltd Composições farmacêuticas que compreendem cefepima ou sulbactama
MY196240A (en) 2014-11-17 2023-03-24 Entasis Therapeutics Ltd Combination Therapy for Treatment Of Resistant Bacterial Infections
RU2589929C1 (ru) * 2015-08-12 2016-07-10 Олег Иванович Квасенков Способ производства хлебного кваса
DK3512851T3 (en) 2016-09-16 2022-10-17 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
AU2018266640B2 (en) 2017-05-08 2022-03-03 Entasis Therapeutics, Inc. Compounds and methods for treating bacterial infections
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109864970A (zh) * 2019-04-22 2019-06-11 苏州东瑞制药有限公司 一种舒巴坦钠组合物无菌粉及其制备方法
CN113559099A (zh) * 2021-08-27 2021-10-29 丹诺医药(苏州）有限公司 包含舒巴坦和阿维巴坦的药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE319447T1 (de) 1999-08-16 2006-03-15 Revaax Pharmaceuticals Llc Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
EP2015755A4 (en) * 2006-04-28 2010-02-24 Wockhardt Ltd ENHANCED TREATMENT FOR TREATING BACTERIAL RESISTANT INFECTIONS
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
CN102106857B (zh) * 2009-12-29 2012-07-18 齐鲁动物保健品有限公司 注射用复方头孢噻呋钠冻干粉针剂

Also Published As

Publication number Publication date
CA2842777C (en) 2015-12-29
EP2736508A1 (en) 2014-06-04
KR20140053900A (ko) 2014-05-08
CA2842777A1 (en) 2013-01-31
JP2014521631A (ja) 2014-08-28
AU2011373911B2 (en) 2016-09-22
US9744160B2 (en) 2017-08-29
JP5808860B2 (ja) 2015-11-10
KR101737167B1 (ko) 2017-05-17
CN103687598A (zh) 2014-03-26
CN103687598B (zh) 2016-03-16
US20140094447A1 (en) 2014-04-03
RU2560846C1 (ru) 2015-08-20
MX2013015002A (es) 2014-10-22
WO2013014496A1 (en) 2013-01-31
BR112013032711A2 (pt) 2017-01-17
ZA201307956B (en) 2015-01-28
NZ616806A (en) 2015-03-27
AU2011373911A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
MX338610B (es) Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
NZ617104A (en) Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
EP4349820A3 (en) Compounds and compositions for treating conditions associated with nlrp activity
MX2016011468A (es) Inhibidores de calicreína plasmática humana.
WO2013122888A3 (en) Methods of treating bacterial infections
PH12017500852A1 (en) Combination therapy for treatment of resistant bacterial infections
MX2019010602A (es) Inhibidores de cdk.
IN2014DN10670A (es)
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
TN2012000458A1 (en) Uses of dgat1 inhibitors
GEP20186876B (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
NZ706734A (en) Pharmaceutical compositions useful for the treatment or control of bacterial infections
MX2015013151A (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
PH12015501036A1 (en) A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
AU2012225365A8 (en) Peptide deformylase inhibitors
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX2016005869A (es) Inhibidor de beta-lactamasa cristalina.
JOP20120346B1 (ar) مركبات لعلاج ومنع الإلتصاق، وتركيبات صيدلية متعلقة بالمركب وطرق لمنع وعلاج الإلتصاقات
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch
MY171941A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
FG Grant or registration